Idiosyncratic drug reactions: Current understanding

Annual Review of Pharmacology and Toxicology

Volumn 47, Issue , 2007, Pages 513-539

  Uetrecht, Jack ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adverse drug reactions; Biomarkers; Genetic polymorphism; Reactive metabolites; Tolerance

Indexed keywords

ALLOPURINOL; AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; CARBAMAZEPINE; CLOZAPINE; CYCLOOXYGENASE 2; DICLOFENAC; FELBAMATE; HALOTHANE; HAPTEN; HLA ANTIGEN; HLA B ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; ISONIAZID; LIPOPOLYSACCHARIDE; MESSENGER RNA; NEVIRAPINE; PARACETAMOL; PENICILLAMINE; PENICILLIN DERIVATIVE; PHENOBARBITAL; PHENYTOIN; PIPERANOMETOZINE; PROCAINAMIDE; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID;

AGRANULOCYTOSIS; ALLERGY; DRUG EFFECT; DRUG INDUCED DISEASE; HEPATITIS; HLA SYSTEM; HUMAN; HYPERSENSITIVITY; HYPOTHESIS; IMMUNITY; IMMUNOGENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; LIVER TOXICITY; METABOLISM; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; BIOLOGICAL MARKERS; HLA ANTIGENS; HUMANS; MODELS, ANIMAL; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS;

ANIMALIA;

EID: 33847081148     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.47.120505.105150     Document Type: Review

References (101)

1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. 2004. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Brit. Med. J. 329:15-19
2. Demoly P, Bousquet J. 2001. Epidemiology of drug allergy. Curr. Opin. Allergy Clin. Immunol. 1:305-10
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. 2002. Timing of new Black Box Warnings and withdrawals for prescription medications. J. Am. Med. Assoc. 287:2215-20
4. Frank R, Hargreaves R. 2003. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2:566-80
5. Uetrecht JP. 1992. The role of leukocyte-generated metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab. Rev. 24:299-366
6. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP, Banks PM. 2006. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann. Intern. Med. 144:415-20
7. Graham DJ, Green L, Senior JR, Nourjah P. 2003. Troglitazone-induced liver failure: a case study. Am. J. Med. 114:299-306
8. Guest I, Sokoluk B, MacCrimmon J, Uetrecht J. 1998. Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 131:53-65
9. Warkentin TE, Kelton JG. 2001. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344:1286-92
10. Dossing M, Wilcke JT, Askgaard DS, Nybo B. 1996. Liver injury during anti-tuberculosis treatment: an 11-year study. Tuber. Lung Dis. 77:335-40
11. Cameron HA, Ramsay LE. 1984. The lupus syndrome induced by hydralazine: a common complication with low dose therapy. Br. Med. J. 289:410-12
12. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, et al. 1998. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N. Engl. J. Med. 339:1810-16
13. Uetrecht JP. 1999. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem. Res. Toxicol. 12:387-95
14. Watkins PB. 2005. Idiosyncratic liver injury: challenges and approaches. Toxicol. Pathol. 33:1-5
15. Uetrecht JP, Woosley RL. 1981. Acetylator phenotype and lupus erythematosus. Clin. Pharmacokin. 6:118-34
16. Hyson C, Sadler M. 1997. Cross sensitivity of skin rashes with antiepileptic drugs. Can. J. Neurol. Sci. 24:245-49
17. Shear NH, Spielberg SP. 1988. Anticonvulsant hypersensitivity syndrome. J. Clin. Invest. 82:1826-32
18. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, et al. 2002. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137:947-54
19. Lee WM. 2003. Acute liver failure in the United States. Semin. Liver Dis. 23:217-26
20. Gow PJ, Jones RM, Dobson JL, Angus PW. 2004. Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. J. Gastroenterol. Hepatol. 19:154-59
21. Zimmerman H. 1999. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia, PA: Lippincott Williams & Wilkins
22. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. 2000. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin. Exp. Allergy 30:847-55
23. Bachot N, Roujeau JC. 2003. Differential diagnosis of severe cutaneous drug eruptions. Am. J. Clin. Dermatol. 4:561-72
24. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, et al. 2002. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883-89
25. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. 1991. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin. Pharmcol. Ther. 49:13-17
26. O'Neil WM, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, et al. 2002. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J. Clin. Pharmacol. 42:613-19
27. Leeder JS. 1998. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 39:S8-16
28. Pirmohamed M, Park BK. 2001. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22:298-305
29. Batchelor JR, Welsh KI, Tinoco RM, Dollery CT, Hughes GRV, et al. 1980. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1:1107-9
30. Claas FH, Abbott PA, Witvliet MD, D'Amaro J, Barnes PM, Krupp P. 1992. No direct clinical relevance of the human leukocyte antigen (HLA) system in clozapine-induced agranulocytosis. Drug Saf. 7:3-6
31. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. 1990. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch. Gen. Psychiatry 47:945-48
32. Andrade RJ, Lucena MI, Alonso A, Garcia-Cortes M, Garcia-Ruiz E, et al. 2004. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39:1603-12
33. Berson A, Freneaux E, Larrey D, Lepage V, Douay C, et al. 1994. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J. Hepatol. 20:336-42
34. Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, et al. 1999. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117:1181-86
35. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, et al. 2004. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39:1430-40
36. Mallal S, Nolan D, Witt C, Masel G, Martin AM, et al. 2002. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-32
37. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, et al. 2004. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. USA 101:4180-85
38. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, et al. 2004. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5:203-11
39. Phillips EJ. 2006. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin. Infect. Dis. 43:103-5
40. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, et al. 2005. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 102:4134-39
41. Walton B, Simpson BR, Strunin L, Doniach D, Perrin J, Appleyard AJ. 1976. Unexplained hepatitis following halothane. Br. Med. J. 1:1171-76
42. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. 1993. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 329:162-67
43. Lee WM. 2003. Drug-induced hepatotoxicity. N. Engl. J. Med. 349:474-85
44. Russo MW, Watkins PB. 2004. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology 126:1477-80
45. Pullen H, Wright N, Murdoch J. 1967. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 2:1176-78
46. van der Ven AJAM, Koopmans PP, Vree TB, van der Meer JWM. 1991. Adverse reactions to cotrimoxazole in HIV infection. Lancet 338:431-33
47. Kano Y, Inaoka M, Shiohara T. 2004. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch. Dermatol. 140:183-88
48. Boelsterli UA. 2003. Disease-related determinants of susceptibility to drug-induced idiosyncratic hepatotoxicity. Curr. Opin. Drug Discov. Devel. 6:81-91
49. Waldhauser L, Uetrecht J. 1996. Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat. Toxicology 114:155-62
50. Seguin B, Boutros PC, Li X, Okey AB, Uetrecht JP. 2005. Gene expression profiling in a model of D-penicillamine-induced autoimmunity in the Brown Norway rat: predictive value of early signs of danger. Chem. Res. Toxicol. 18:1193-202
51. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. 1994. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J. Am. Med. Assoc. 271:992-98
52. Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. 2002. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 100:1185-91
53. Park K, Williams DP, Naisbitt DJ, Kitteringham NR, Pirmohamed M. 2005. Investigation of toxic metabolites during drug development. Toxicol. Appl. Pharmacol. 207:425-34
54. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, et al. 2005. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6:161-225
55. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. 2004. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17:3-16
56. Langman RE, Cohn M. 2000. Self-nonself discrimination revisited. Introduction. Semin. Immunol. 12:159-62
57. Landsteiner K, Jacobs J. 1935. Studies on the sensitization of animals with simple chemical compounds. J. Exp. Med. 61:643-56
58. Parker CW. 1982. Allergic reactions in man. Pharmacol. Rev. 34:85-104
59. Vergani D, Mieli-Vergani G, Alberti A, Neuberger J, Eddleston A, et al. 1980. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med. 303:66-71
60. Lecoeur S, Andre C, Beaune PH. 1996. Tienilic acid-induced autoimmune hepatitis: antiliver and kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol. Pharmacol. 50:326-33
61. Uetrecht J. 2001. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug. Discov. Devel. 4:55-59
62. Matzinger P. 1994. Tolerance, danger and the extended family. Annu. Rev. Immunol. 12:991-1045
63. Matzinger P. 1998. An innate sense of danger. Semin. Immunol. 10:399-415
64. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. 2002. The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology 181-182:55-63
65. Seguin B, Uetrecht J. 2003. The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol. 3:235-42
66. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, et al. 1998. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alphabeta T lymphocytes. J. Clin. Invest. 102:1591-98
67. Pichler WJ. 2002. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr. Opin. Allergy Clin. Immunol. 2:301-5
68. Thierse HJ, Gamerdinger K, Junkes C, Guerreiro N, Weltzien HU. 2005. T cell receptor (TCR) interaction with haptens: metal ions as nonclassical haptens. Toxicology 209:101-7
69. Fontenot AP, Kotzin BL. 2003. Chronic beryllium disease: immune-mediated destruction with implications for organ-specific autoimmunity. Tissue Antig. 62:449-58
70. Uetrecht J. 2002. N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab. Rev. 34:651-65
71. Hopkins JE, Naisbitt DJ, Humphreys N, Dearman RJ, Kimber I, Park BK. 2005. Exposure of mice to the nitroso metabolite of sulfamethoxazole stimulates interleukin 5 production by CD4+ T-cells. Toxicology 206:221-31
72. Naisbitt DJ, Gordon SF, Pirmohamed M, Burkhart C, Cribb AE, et al. 2001. Antigenicity and immunogenicity of sulfamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br. J. Pharmacol. 133:295-305
73. Bourdi M, Masubuchi Y, Reilly TP, Amouzadeh HR, Martin JL, et al. 2002. Protection against acetaminophe-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 35:289-98
74. Bourdi M, Reilly TP, Elkahloun AG, George JW, Pohl LR. 2002. Macrophage migration inhibitory factor in drug-induced liver injury: a role in susceptibility and stress responsiveness. Biochem. Biophys. Res. Commun. 294:225-30
75. Ju C, Reilly TP, Bourdi M, Radonovich MF, Brady JN, et al. 2002. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem. Res. Toxicol. 15:1504-13
76. Liu ZX, Govindarajan S, Kaplowitz N. 2004. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 127:1760-74
77. Chojkier M. 2005. Troglitazone and liver injury: in search of answers. Hepatology 41:237-46
78. Pessayre D, Mansouri A, Haouzi D, Fromenty B. 1999. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol. 15:367-73
79. Krahenbuhl S, Brandner S, Kleinle S, Liechti S, Straumann D. 2000. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 20:346-48
80. Roth RA, Luyendyk JP, Maddox JF, Ganey PE. 2003. Inflammation and drug idiosyncrasy-is there a connection? J. Pharmacol. Exp. Ther. 307:1-8
81. Shenton JM, Chen J, Uetrecht JP. 2004. Animal models of idiosyncratic drug reactions. Chem. Biol. Interact. 150:53-70
82. Trepanier LA. 2004. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J. Vet. Pharmacol. Ther. 27:129-38
83. Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. 2003. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 307:9-16
84. Furst SM, Luedke D, Gaw HH, Reich R, Gandolfi AJ. 1997. Demonstration of a cellular immune response in halothane-exposed guinea pigs. Toxicol. Appl. Pharmacol. 143:245-55
85. Stein HB, Patterson AC, Offer RC, Atkins CJ, Teufel A, Robinson HS. 1980. Adverse effects of D-penicillamine in rheumatoid arthritis. Ann. Intern. Med. 92:24-29
86. Donker AJ, Venuto RC, Vladutiu AO, Brentjens JR, Andres GA. 1984. Effects of prolonged administration of D-penicillamine or captopril in various strains of rats. Clin. Immunol. Immunopath. 30:142-55
87. Tournade H, Pelletier L, Pasquier R, Vial M, Mandet C, Druet P. 1990. D-Penicillamine-induced autoimmunity in Brown-Norway rats: similarities with HgCl2-induced autoimmunity. J. Immunol. 144:2985-91
88. Masson MJ, Uetrecht JP. 2004. Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. Chem. Res. Toxicol. 17:82-94
89. Masson MJ, Teranishi M, Shenton JM, Uetrecht JP. 2004. Investigation of the involvement of macrophages and T cells in D-penicillamine-induced autoimmunity in the Brown Norway rat. J. Immmunotoxicol. 1:79-93
90. Sayeh E, Uetrecht JP. 2001. Factors that modify penicillamine-induced autoimmunity in Brown Norway rats: failure of the Th1/Th2 paradigm. Toxicology 163:195-211
91. Howard-Lock HE, Lock CJ, Mewa A, Kean WF. 1986. D-Penicillamine: chemistry and clinical use in rheumatic disease. Semin. Arthritis Rheum. 15:261-81
92. Rhodes J. 1989. Evidence for an intercellular covalent reaction essential in antigen-specific T cell activation. J. Immunol. 143:1482-89
93. Uetrecht J. 2005. Current trends in drug-induced autoimmunity. Autoimmun. Rev. 4:309-14
94. Pollard R, Robinson P, Dransfield K. 1998. Safety profile of nevirapine, a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Ther. 20:1071-92
95. Bersoff-Matcha S, Miller W, Aberg J, van Der Horst C, Hamrick JH, et al. 2001. Sex differences in nevirapine rash. Clin. Infect. Dis. 32:124-29
96. Shenton JM, Teranishi M, Abu-Asab MS, Yager JA, Uetrecht JP. 2003. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res. Toxicol. 16:1078-89
97. Shenton JM, Popovic M, Chen J, Masson MJ, Uetrecht JP. 2005. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem. Res. Toxicol. 18:1799-813
98. Barreiro P, Soriano V, Casas E, Estrada V, Tellez MJ, et al. 2000. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. Aids 14:2153-57
99. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, et al. 1999. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Disp. 27:895-901
100. Meisheri KD, Johnson GA, Puddington L. 1993. Enzymatic and nonenzymatic sulfation mechanisms in the biological actions of minoxidil. Biochem. Pharmacol. 45:271-79
101. Ju C. 2005. Immunological mechanisms of drug-induced liver injury. Curr. Opin. Drug Discov. Devel. 8:38-43